Boston Scientific Stock: Is BSX Underperforming the Healthcare Sector?

Valued at a market cap of $71.8 billion, Boston Scientific Corporation (BSX) develops, manufactures, and markets minimally invasive medical devices and therapies. The Marlborough, Massachusetts-based company specializes in creating highly engineered medical technologies used across a broad spectrum of subspecialties to diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions.

Companies worth $10 billion or more are typically classified as “large-cap stocks,” and BSX fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the medical devices industry. The company’s primary strength lies in its "category leadership" strategy, which focuses heavily on high-growth, procedure-heavy medical fields where it can establish dominant, clinically differentiated positions rather than attempting to be a generalist hospital supplier.